Teva Pharm sees nationwide U.S. opioid settlement in 2022
Chinese Developers Face Liquidity Test; Teva, Nordstrom, Sappi Downgraded; Macy's Q2 Earnings Beat Estimates - Track Live Bond Prices Online with BondEValue App -
Celltrion's manufacturing headache likely to delay Teva migraine drug until 2019: analysts | Fierce Pharma